Literature DB >> 16264094

Estrogenic induction of spermatogenesis in the hypogonadal (hpg) mouse: role of androgens.

Helen Baines1, Margaret O Nwagwu, Edwina C Furneaux, Jane Stewart, Jeffrey B Kerr, Terry M Mayhew, Francis J P Ebling.   

Abstract

Testicular development is arrested in the hypogonadal (hpg) mouse due to a congenital deficiency of hypothalamic gonadotropin-releasing hormone synthesis. Previous studies have demonstrated that chronic treatment of these mice with estradiol induces testicular maturation and qualitatively normal spermatogenesis, but it is not known whether these are direct effects via estrogen receptors expressed in the testis, or indirect actions via the pituitary gland. The aim of the current studies was to determine whether the actions of estradiol require the presence of androgens. Sensitive assays revealed that chronic estradiol treatment produced time-dependent increases in pituitary FSH production but no increases in pituitary LH or testicular testosterone content could be detected. As a functional test of androgen dependence, hpg mice were treated for 70 days with estradiol plus Casodex (bicalutamide), an androgen receptor antagonist. Casodex treatment markedly attenuated both the estradiol-induced increase in testicular weight and the proliferation of the seminiferous epithelium, as revealed by morphometric analysis. However, it did not affect the estradiol-induced increase in pituitary FSH content, nor did it affect estradiol-induced increases in the weight of the seminal vesicles and epididymides. We conclude that increased FSH production is not sufficient to explain the increase in testicular development induced by estradiol in hpg mice; there is a requirement for functional androgen receptors for induction of testicular growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16264094     DOI: 10.1530/rep.1.00693

Source DB:  PubMed          Journal:  Reproduction        ISSN: 1470-1626            Impact factor:   3.906


  7 in total

1.  Temporal role of Sertoli cell androgen receptor expression in spermatogenic development.

Authors:  Rasmani Hazra; Lisa Corcoran; Mat Robson; Kirsten J McTavish; Dannielle Upton; David J Handelsman; Charles M Allan
Journal:  Mol Endocrinol       Date:  2012-11-16

2.  Estradiol induction of spermatogenesis is mediated via an estrogen receptor-{alpha} mechanism involving neuroendocrine activation of follicle-stimulating hormone secretion.

Authors:  Charles M Allan; John F Couse; Ulla Simanainen; Jenny Spaliviero; Mark Jimenez; Karina Rodriguez; Kenneth S Korach; David J Handelsman
Journal:  Endocrinology       Date:  2010-04-21       Impact factor: 4.736

3.  Effects of the methanol extract of Basella alba L (Basellaceae) on steroid production in Leydig cells.

Authors:  Edouard Akono Nantia; Carine Travert; Faustin-Pascal T Manfo; Serge Carreau; Thomas K Monsees; Paul Fewou Moundipa
Journal:  Int J Mol Sci       Date:  2011-01-14       Impact factor: 5.923

4.  Neonatal androgenization of hypogonadal (hpg) male mice does not abolish estradiol-induced FSH production and spermatogenesis.

Authors:  Margaret O Nwagwu; Helen Baines; Jeffrey B Kerr; Francis J P Ebling
Journal:  Reprod Biol Endocrinol       Date:  2005-09-21       Impact factor: 5.211

5.  Expression analysis of gnrh1 and gnrhr1 in spermatogenic cells of rat.

Authors:  Vincenza Ciaramella; Rosanna Chianese; Paolo Pariante; Silvia Fasano; Riccardo Pierantoni; Rosaria Meccariello
Journal:  Int J Endocrinol       Date:  2015-03-12       Impact factor: 3.257

6.  Effects of estradiol and FSH on maturation of the testis in the hypogonadal (hpg) mouse.

Authors:  Helen Baines; Margaret O Nwagwu; Graham R Hastie; Roman A Wiles; Terry M Mayhew; Francis Jp Ebling
Journal:  Reprod Biol Endocrinol       Date:  2008-01-29       Impact factor: 5.211

Review 7.  Role of estrogen receptors and g protein-coupled estrogen receptor in regulation of hypothalamus-pituitary-testis axis and spermatogenesis.

Authors:  Adele Chimento; Rosa Sirianni; Ivan Casaburi; Vincenzo Pezzi
Journal:  Front Endocrinol (Lausanne)       Date:  2014-01-16       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.